WASHINGTON — AstraZeneca has decided to leave the brand drug lobbying powerhouse PhRMA halfway through the year, the organization said.
The exit is the group’s third in five months, as AbbVie exited PhRMA in December and Teva Pharmaceuticals left in February.
PhRMA, which confirmed AstraZeneca’s departure, said in a statement the group continues to prioritize “pushing reforms that protect innovation and make health care more accessible and affordable for all Americans.”
Create a display name to comment
This name will appear with your comment